As a result, an improved sensitivity of 79.49% (95%CI: 64.47%-89.22%) with the specificity of 63.04% (95%CI:48.60%-75.48%) was for cMLC-1 to predict HER2- breast cancer with the cutoff at 37.17 ng/mL. The gene discussed is ERBB2; the disease is breast carcinoma.